innovation needed , page-3

Hi Jov,
You raise a good point in asking why we have not yet reached the phase where advance payments have been made and deals signed.


I refer you to abdm's last post which impressively shows the positive development with only ONE partner up to this point.
If a partner company is already in consumer acceptance testing for a product it shows that all previous testing and evaluation steps have been ticked and the partner company repeatedly signed new contracts and agreement up to this point.
This ( first ) FMCG is just one single step away from coming forward and announcing an official partnership, there are no steps left in the regulatory hurdles regime which biotech companies have to follow to the dot and take years to complete.

There is no shortcut in healthcare related innovations to hit market, hence the predicament of the whole industry as such processes are cost intensive and only bring revenue after years and years and testing ( that is why big pharma companies prefer to partner up with small research companies to avoid large costs for development of their own ).


This is the reason why OBJ diversified into OTC products and developed the FIM technology, which was ordered by one of our partners ( I believe it to be GSK ).

The last GSK announcement shows that GSK has stepped up its commitment after a " Short Term Agreement ", no short terms in biotech as it took them more than half a year to rn its course, and announced a FIM development with OBJ scientists sharing the GSK labatories in Europe.
This is a major step and, in my opinion, a milestone in OBJ's history.

This leads me straight to my next point.
Why do we not see a higher share price then?

Traditionally, when companies move away from being a pure speculative play to a calculated play, trading patterns move away from speculative spikes and dumps to accumulation and eventually to a large rerating when the news come out which are preparing themselves currently.

The Strategic Alliance is the third concrete development for OBJ and is with a new partner we did not hear about before ( many believe this to be a cosmetic company ).
We are therefore expecting updates from 3 partner companies, plus the unexpected, which seems to be the most likely with OBJ.


If you compare other breakthrough companies with similar innovative technologies, there are many steps to be ticked until the rerating breakthrough event.
Many posters here who have followed OBJ for years believe that we are just at this point in time.
The bonus for new investors is that we are still at very low price levels which allows to step in with very low risk ratios and be part of an exciting development story of an Australian biotech company making its mark internationally.


Hope that helped,
good luck with your investment!